{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:01:48Z","timestamp":1790240508455,"version":"4.1.0"},"reference-count":43,"publisher":"Massachusetts Medical Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NEJM Evidence"],"published-print":{"date-parts":[[2024,9,24]]},"DOI":"10.1056\/evidoa2400189","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T21:00:25Z","timestamp":1726261225000},"source":"Crossref","is-referenced-by-count":43,"title":["Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022\u20132023"],"prefix":"10.1056","volume":"3","author":[{"given":"Patricia A.","family":"Yu","sequence":"first","affiliation":[{"name":"Office of Readiness and Response, Centers for Disease Control and Prevention, Atlanta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Elmor","sequence":"additional","affiliation":[{"name":"Booz Allen Hamilton, McLean, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalimah","family":"Muhammad","sequence":"additional","affiliation":[{"name":"Office of Readiness and Response, Centers for Disease Control and Prevention, Atlanta"},{"name":"Cherokee Nation Integrated Health, Tulsa, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yon C.","family":"Yu","sequence":"additional","affiliation":[{"name":"Office of Readiness and Response, Centers for Disease Control and Prevention, Atlanta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agam K.","family":"Rao","sequence":"additional","affiliation":[{"name":"Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.22.2127"},{"key":"e_1_3_5_3_2","unstructured":"SIGA Technologies Inc. TPOXX prescribing information. 2022 (https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/208627s007lbl.pdf)."},{"key":"e_1_3_5_4_2","unstructured":"U.S. Food and Drug Administration. Animal rule information. March 25 2024 (https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-regulatory-science\/animal-rule-information)"},{"key":"e_1_3_5_5_2","unstructured":"U.S. Food and Drug Administration. FDA approves the first drug with an indication for treatment of smallpox. July 13 2018 (https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-indication-treatment-smallpox)."},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis510"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz286"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6842a2"},{"key":"e_1_3_5_9_2","unstructured":"Centers for Disease Control and Prevention. 2022 outbreak cases and data. March 5 2024 (https:\/\/www.cdc.gov\/poxvirus\/mpox\/response\/2022\/index.html)."},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29198"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2023.102544"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7132e3"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207323"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.Es.2023.28.12.2200772"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.Es.2022.27.36.2200620"},{"key":"e_1_3_5_16_2","unstructured":"World Health Organization. 2022\u20132023 Mpox (monkeypox) outbreak: Global trends. August 22 2024 (https:\/\/worldhealthorg.shinyapps.io\/mpx_global\/)."},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2912.231146"},{"key":"e_1_3_5_18_2","unstructured":"U.S. Food and Drug Administration. FDA mpox response. August 15 2024 (https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-issues\/fda-mpox-response)."},{"key":"e_1_3_5_19_2","unstructured":"Centers for Disease Control and Prevention. Mpox treatment information for healthcare professionals. August 16 2024 (https:\/\/www.cdc.gov\/poxvirus\/mpox\/clinicians\/treatment.html)."},{"key":"e_1_3_5_20_2","unstructured":"Centers for Disease Control and Prevention. Clinical considerations for pain management of mpox. March 27 2023 (https:\/\/www.cdc.gov\/poxvirus\/mpox\/clinicians\/pain-management.html)."},{"key":"e_1_3_5_21_2","unstructured":"Administration for Strategic Preparedness & Response. Distribution from the strategic national stockpile Pre-positioning and contingency supplies. July 2024 (https:\/\/aspr.hhs.gov\/Mpox\/TPOXXOperationalGuidance\/Pages\/distribution.aspx)."},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7209a4"},{"key":"e_1_3_5_23_2","unstructured":"Centers for Disease Control and Prevention. Tecovirimat (TPOXX) for treatment of mpox. July 9 2024 (https:\/\/www.cdc.gov\/poxvirus\/mpox\/clinicians\/tecovirimat-ea-ind.html)."},{"key":"e_1_3_5_24_2","unstructured":"Centers for Disease Control and Prevention. Expanded access IND protocol: Use of tecovirimat (TPOXX\u00ae) for treatment of human non-variola orthopoxvirus infections in adults and children. June 5 2024 (https:\/\/www.cdc.gov\/poxvirus\/mpox\/pdf\/Tecovirimat-IND-Protocol-CDC-IRB.pdf)."},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1109\/tvcg.2014.2346248"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btx364"},{"key":"e_1_3_5_27_2","unstructured":"Centers for Disease Control and Prevention. JYNNEOS vaccine: Interim guidance. April 22 2024 (https:\/\/www.cdc.gov\/poxvirus\/mpox\/interim-considerations\/jynneos-vaccine.html)."},{"key":"e_1_3_5_28_2","unstructured":"Bavarian Nordic A\/S. JYNNEOS \u2014 vaccinia virus modified strain Ankara Bavarian Nordic non-replicating antigen injection suspension. Prescribing information. November 15 2023 (https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=69fc3841-a461-4706-bdcb-1176c40bf486)."},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.09.004"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2023.11.025"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.7696"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.15336"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae029"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2911.230814"},{"key":"e_1_3_5_35_2","unstructured":"Lescure X Merson L Laou\u00e9nan C et al. MOSAIC clade 2b Mpox cohort study: clinical characterisation and outcomes. Conference on Retroviruses and Opportunistic Infections (CROI). Seattle WA 2023 (https:\/\/www.croiconference.org\/preliminary-agenda-2023\/)."},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2210015"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.7326\/m22-3132"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7138e3"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)02187-0"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad552"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00972-23"},{"key":"e_1_3_5_42_2","doi-asserted-by":"crossref","unstructured":"Gigante CG Takakuwa J McGrath D et al. Notes from the field: Tecovirimat-resistant monkeypox virus cluster \u2014 five states October 2023\u2013February 2024. Morb Mortal Wkly Rep (in press).","DOI":"10.15585\/mmwr.mm7340a3"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.Cd015769"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/156.2.293"}],"container-title":["NEJM Evidence"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T22:13:21Z","timestamp":1751494401000},"score":1,"resource":{"primary":{"URL":"https:\/\/evidence.nejm.org\/doi\/10.1056\/EVIDoa2400189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,9,24]]}},"alternative-id":["10.1056\/EVIDoa2400189"],"URL":"https:\/\/doi.org\/10.1056\/evidoa2400189","relation":{},"ISSN":["2766-5526"],"issn-type":[{"value":"2766-5526","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,24]]}}}